{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T09:05:07Z","timestamp":1791363907237,"version":"4.3.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T00:00:00Z","timestamp":1607472000000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["Grant Agreement No 777204."],"award-info":[{"award-number":["Grant Agreement No 777204."]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiovascular disease that affects approximately one in 500 people. HCM is a recognized genetic disorder most often caused by mutations involving myosin-binding protein C (MYBPC3) and \u03b2-myosin heavy chain (MYH7) which are responsible for approximately three-quarters of the identified mutations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      As a part of the international multidisciplinary SILICOFCM project (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.silicofcm.eu\">www.silicofcm.eu<\/jats:ext-link>\n                      ) the present study evaluated the association between underlying genetic mutations and clinical phenotype in patients with HCM. Only patients with confirmed single pathogenic mutations in either MYBPC3 or MYH7 genes were included in the study and divided into two groups accordingly. The MYBPC3 group was comprised of 48 patients (76%), while the MYH7 group included 15 patients (24%). Each patient underwent clinical examination and echocardiography.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The most prevalent symptom in patients with MYBPC3 was dyspnea (44%), whereas in patients with MYH7 it was palpitations (33%). The MYBPC3 group had a significantly higher number of patients with a positive family history of HCM (46% vs. 7%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.014). There was a numerically higher prevalence of atrial fibrillation in the MYH7 group (60% vs. 35%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.085). Laboratory analyses revealed normal levels of creatinine (85.5\u2009\u00b1\u200918.3 vs. 81.3\u2009\u00b1\u200916.4\u00a0\u00b5mol\/l;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.487) and blood urea nitrogen (10.2\u2009\u00b1\u200915.6 vs. 6.9\u2009\u00b1\u20093.9\u00a0mmol\/l;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.472) which were similar in both groups. The systolic anterior motion presence was significantly more frequent in patients carrying MYH7 mutation (33% vs. 10%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.025), as well as mitral leaflet abnormalities (40% vs. 19%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.039). Calcifications of mitral annulus were registered only in MYH7 patients (20% vs. 0%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001). The difference in diastolic function, i.e. E\/e\u2032 ratio between the two groups was also noted (MYBPC3 8.8\u2009\u00b1\u20093.3, MYH7 13.9\u2009\u00b1\u20096.9,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.079).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Major findings of the present study corroborate the notion that MYH7 gene mutation patients are presented with more pronounced disease severity than those with MYBPC3.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-020-01807-4","type":"journal-article","created":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T13:18:08Z","timestamp":1607519888000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Genetic determinants of clinical phenotype in hypertrophic cardiomyopathy"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2907-819X","authenticated-orcid":false,"given":"Lazar","family":"Velicki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djordje G.","family":"Jakovljevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrej","family":"Preveden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miodrag","family":"Golubovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija","family":"Bjelobrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Ilic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snezana","family":"Stojsic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Barlocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Tafelmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nduka","family":"Okwose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milorad","family":"Tesic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dejana","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arsen","family":"Ristic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy A.","family":"MacGowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nenad","family":"Filipovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars S.","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Olivotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,9]]},"reference":[{"issue":"9862","key":"1807_CR1","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S0140-6736(12)60397-3","volume":"381","author":"BJ Maron","year":"2013","unstructured":"Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet. 2013;381(9862):242\u201355.","journal-title":"Lancet"},{"issue":"20","key":"1807_CR2","first-page":"1977","volume":"379","author":"BJ Maron","year":"2018","unstructured":"Maron BJ. Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med. 2018;379(20):1977.","journal-title":"N Engl J Med"},{"issue":"24","key":"1807_CR3","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1161\/CIR.0b013e318223e230","volume":"124","author":"BJ Gersh","year":"2011","unstructured":"Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF\/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Circulation. 2011a;124(24):2761\u201396.","journal-title":"Circulation"},{"issue":"1","key":"1807_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jacc.2014.05.003","volume":"64","author":"BJ Maron","year":"2014","unstructured":"Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol. 2014;64(1):83\u201399.","journal-title":"J Am Coll Cardiol"},{"issue":"39","key":"1807_CR5","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","volume":"35","author":"PM Elliott","year":"2014","unstructured":"Authors\/Task Force Members, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733\u201379.","journal-title":"Eur Heart J"},{"issue":"11","key":"1807_CR6","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1161\/CIRCULATIONAHA.110.950089","volume":"122","author":"T Force","year":"2010","unstructured":"Force T, Bonow RO, Houser SR, Solaro RJ, Hershberger RE, Adhikari B, et al. Research priorities in hypertrophic cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood Institute. Circulation. 2010;122(11):1130\u20133.","journal-title":"Circulation"},{"issue":"5","key":"1807_CR7","doi-asserted-by":"publisher","first-page":"e006657","DOI":"10.1161\/JAHA.117.006657","volume":"7","author":"DY Lu","year":"2018","unstructured":"Lu DY, Pozios I, Haileselassie B, Ventoulis I, Liu H, Sorensen LL, et al. Clinical outcomes in patients with nonobstructive, labile, and obstructive hypertrophic cardiomyopathy. J Am Heart Assoc. 2018;7(5):e006657.","journal-title":"J Am Heart Assoc"},{"issue":"24","key":"1807_CR8","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1136\/heartjnl-2013-303939","volume":"99","author":"LR Lopes","year":"2013","unstructured":"Lopes LR, Rahman MS, Elliott PM. A systematic review and meta-analysis of genotype-phenotype associations in patients with hypertrophic cardiomyopathy caused by sarcomeric protein mutations. Heart. 2013;99(24):1800\u201311.","journal-title":"Heart"},{"issue":"2","key":"1807_CR9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.hfc.2017.12.004","volume":"14","author":"AC Garfinkel","year":"2018","unstructured":"Garfinkel AC, Seidman JG, Seidman CE. Genetic pathogenesis of hypertrophic and dilated cardiomyopathy. Heart Fail Clin. 2018;14(2):139\u201346.","journal-title":"Heart Fail Clin"},{"issue":"6","key":"1807_CR10","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/S0025-6196(11)60890-2","volume":"83","author":"I Olivotto","year":"2008","unstructured":"Olivotto I, Girolami F, Ackerman MJ, Nistri S, Bos JM, Zachara E, et al. Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Mayo Clin Proc. 2008;83(6):630\u20138.","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"1807_CR11","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/ncpcardio1110","volume":"5","author":"A Keren","year":"2008","unstructured":"Keren A, Syrris P, McKenna WJ. Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression. Nat Clin Pract Cardiovasc Med. 2008;5(3):158\u201368.","journal-title":"Nat Clin Pract Cardiovasc Med"},{"issue":"2","key":"1807_CR12","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s41436-018-0046-0","volume":"21","author":"F Mazzarotto","year":"2019","unstructured":"Mazzarotto F, Girolami F, Boschi B, Barlocco F, Tomberli A, Baldini K, et al. Defining the diagnostic effectiveness of genes for inclusion in panels: the experience of two decades of genetic testing for hypertrophic cardiomyopathy at a single center. Genet Med. 2019;21(2):284\u201392.","journal-title":"Genet Med"},{"issue":"5","key":"1807_CR13","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ejmg.2010.07.007","volume":"53","author":"G Millat","year":"2010","unstructured":"Millat G, Bouvagnet P, Chevalier P, Dauphin C, Jouk PS, Da Costa A, et al. Prevalence and spectrum of mutations in a cohort of 192 unrelated patients with hypertrophic cardiomyopathy. Eur J Med Genet. 2010;53(5):261\u20137.","journal-title":"Eur J Med Genet"},{"key":"1807_CR14","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/clc.23346","volume":"43","author":"M Tafelmeier","year":"2020","unstructured":"Tafelmeier M, Baessler A, Wagner S, Unsoeld B, Preveden A, Barlocco F, et al. Design of the SILICOFCM study: effect of sacubitril\/valsartan vs lifestyle intervention on functional capacity in patients with hypertrophic cardiomyopathy. Clin Cardiol. 2020;43:430\u201340.","journal-title":"Clin Cardiol"},{"issue":"11","key":"1807_CR15","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1093\/eurjhf\/hfr074","volume":"13","author":"S Waldmuller","year":"2011","unstructured":"Waldmuller S, Erdmann J, Binner P, Gelbrich G, Pankuweit S, Geier C, et al. Novel correlations between the genotype and the phenotype of hypertrophic and dilated cardiomyopathy: results from the German Competence Network Heart Failure. Eur J Heart Fail. 2011;13(11):1185\u201392.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"1807_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s00392-017-1155-5","volume":"107","author":"F Sedaghat-Hamedani","year":"2018","unstructured":"Sedaghat-Hamedani F, Kayvanpour E, Tugrul OF, Lai A, Amr A, Haas J, et al. Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals. Clin Res Cardiol. 2018;107(1):30\u201341.","journal-title":"Clin Res Cardiol"},{"issue":"4","key":"1807_CR17","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.ahj.2013.07.029","volume":"166","author":"JD Marsiglia","year":"2013","unstructured":"Marsiglia JD, Credidio FL, de Oliveira TG, Reis RF, Antunes Mde O, de Araujo AQ, et al. Screening of MYH7, MYBPC3, and TNNT2 genes in Brazilian patients with hypertrophic cardiomyopathy. Am Heart J. 2013;166(4):775\u201382.","journal-title":"Am Heart J"},{"issue":"1","key":"1807_CR18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/S0300-8932(09)70020-X","volume":"62","author":"M Garcia-Castro","year":"2009","unstructured":"Garcia-Castro M, Coto E, Reguero JR, Berrazueta JR, Alvarez V, Alonso B, et al. Mutations in sarcomeric genes MYH7, MYBPC3, TNNT2, TNNI3, and TPM1 in patients with hypertrophic cardiomyopathy. Rev Esp Cardiol. 2009;62(1):48\u201356.","journal-title":"Rev Esp Cardiol"},{"key":"1807_CR19","doi-asserted-by":"publisher","first-page":"11411","DOI":"10.1038\/srep11411","volume":"5","author":"X Liu","year":"2015","unstructured":"Liu X, Jiang T, Piao C, Li X, Guo J, Zheng S, et al. Screening mutations of MYBPC3 in 114 unrelated patients with hypertrophic cardiomyopathy by targeted capture and next-generation sequencing. Sci Rep. 2015;5:11411.","journal-title":"Sci Rep"},{"issue":"2","key":"1807_CR20","doi-asserted-by":"publisher","first-page":"e005311","DOI":"10.1161\/CIRCIMAGING.116.005311","volume":"10","author":"A Weissler-Snir","year":"2017","unstructured":"Weissler-Snir A, Hindieh W, Gruner C, Fourey D, Appelbaum E, Rowin E, et al. Lack of phenotypic differences by cardiovascular magnetic resonance imaging in MYH7 (beta-myosin heavy chain)-versus MYBPC3 (myosin-binding protein C)-related hypertrophic cardiomyopathy. Circ Cardiovasc imaging. 2017;10(2):e005311.","journal-title":"Circ Cardiovasc imaging."},{"issue":"3","key":"1807_CR21","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jacc.2005.04.043","volume":"46","author":"I Olivotto","year":"2005","unstructured":"Olivotto I, Maron MS, Adabag AS, Casey SA, Vargiu D, Link MS, et al. Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46(3):480\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1807_CR22","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s00380-019-01492-0","volume":"35","author":"JH Jang","year":"2020","unstructured":"Jang JH, Shin SH, Beak YS, Ko KY, Kwon SW, Park SD, et al. Impact of gender on heart failure presentation in non-obstructive hypertrophic cardiomyopathy. Heart Vessels. 2020;35(2):214\u201322.","journal-title":"Heart Vessels"},{"issue":"24","key":"1807_CR23","first-page":"e783","volume":"124","author":"BJ Gersh","year":"2011","unstructured":"Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF\/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Circulation. 2011b;124(24):e783-831.","journal-title":"Circulation"},{"issue":"45","key":"1807_CR24","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1093\/eurheartj\/ehz487","volume":"40","author":"C Semsarian","year":"2019","unstructured":"Semsarian C, Ho CY. Screening children at risk for hypertrophic cardiomyopathy: balancing benefits and harms. Eur Heart J. 2019;40(45):3682\u20134.","journal-title":"Eur Heart J"},{"issue":"7","key":"1807_CR25","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","volume":"121","author":"AJ Marian","year":"2017","unstructured":"Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res. 2017;121(7):749\u201370.","journal-title":"Circ Res"},{"issue":"9","key":"1807_CR26","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1161\/CIRCRESAHA.116.309804","volume":"119","author":"T Kraft","year":"2016","unstructured":"Kraft T, Montag J, Radocaj A, Brenner B. Hypertrophic cardiomyopathy: cell-to-cell imbalance in gene expression and contraction force as trigger for disease phenotype development. Circ Res. 2016;119(9):992\u20135.","journal-title":"Circ Res"},{"issue":"5","key":"1807_CR27","first-page":"450","volume":"45","author":"O Hallioglu Kilinc","year":"2017","unstructured":"Hallioglu Kilinc O, Giray D, Bisgin A, Tug Bozdogan S, Karpuz D. Familial hypertrophic cardiomyopathy: a case with a new mutation in the MYBPC3 gene. Turk Kardiyoloji Dernegi arsivi Turk Kardiyoloji Derneginin yayin organidir. 2017;45(5):450\u20133.","journal-title":"Turk Kardiyoloji Dernegi arsivi Turk Kardiyoloji Derneginin yayin organidir"},{"issue":"2","key":"1807_CR28","doi-asserted-by":"publisher","first-page":"e006066","DOI":"10.1161\/CIRCIMAGING.117.006066","volume":"10","author":"A Tower-Rader","year":"2017","unstructured":"Tower-Rader A, Desai MY. Phenotype-genotype correlation in hypertrophic cardiomyopathy: less signal, more noise? Circ Cardiovasc Imaging. 2017;10(2):e006066.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"22","key":"1807_CR29","first-page":"1728","volume":"38","author":"A Weissler-Snir","year":"2017","unstructured":"Weissler-Snir A, Adler A, Williams L, Gruner C, Rakowski H. Prevention of sudden death in hypertrophic cardiomyopathy: bridging the gaps in knowledge. Eur Heart J. 2017;38(22):1728\u201337.","journal-title":"Eur Heart J"},{"issue":"21","key":"1807_CR30","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1161\/hc4601.097997","volume":"104","author":"I Olivotto","year":"2001","unstructured":"Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 2001;104(21):2517\u201324.","journal-title":"Circulation"},{"issue":"9","key":"1807_CR31","doi-asserted-by":"publisher","first-page":"e005191","DOI":"10.1161\/CIRCHEARTFAILURE.118.005191","volume":"11","author":"SP Lee","year":"2018","unstructured":"Lee SP, Ashley EA, Homburger J, Caleshu C, Green EM, Jacoby D, et al. Incident atrial fibrillation is associated with MYH7 sarcomeric gene variation in hypertrophic cardiomyopathy. Circ Heart Fail. 2018;11(9):e005191.","journal-title":"Circ Heart Fail"},{"issue":"7","key":"1807_CR32","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.amjcard.2015.12.058","volume":"117","author":"C Bongini","year":"2016","unstructured":"Bongini C, Ferrantini C, Girolami F, Coppini R, Arretini A, Targetti M, et al. Impact of genotype on the occurrence of atrial fibrillation in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2016;117(7):1151\u20139.","journal-title":"Am J Cardiol"},{"issue":"11","key":"1807_CR33","doi-asserted-by":"publisher","first-page":"e0187948","DOI":"10.1371\/journal.pone.0187948","volume":"12","author":"SK Viswanathan","year":"2017","unstructured":"Viswanathan SK, Sanders HK, McNamara JW, Jagadeesan A, Jahangir A, Tajik AJ, et al. Hypertrophic cardiomyopathy clinical phenotype is independent of gene mutation and mutation dosage. PLoS ONE. 2017;12(11):e0187948.","journal-title":"PLoS ONE"},{"issue":"7","key":"1807_CR34","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.jacc.2008.04.047","volume":"52","author":"I Olivotto","year":"2008","unstructured":"Olivotto I, Maron MS, Autore C, Lesser JR, Rega L, Casolo G, et al. Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2008;52(7):559\u201366.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1807_CR35","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1161\/CIRCHEARTFAILURE.112.967026","volume":"5","author":"I Olivotto","year":"2012","unstructured":"Olivotto I, Cecchi F, Poggesi C, Yacoub MH. Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging. Circ Heart Fail. 2012;5(4):535\u201346.","journal-title":"Circ Heart Fail"},{"issue":"10","key":"1807_CR36","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1136\/hrt.2008.154435","volume":"94","author":"SR Ommen","year":"2008","unstructured":"Ommen SR, Shah PM, Tajik AJ. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: past, present and future. Heart. 2008;94(10):1276\u201381.","journal-title":"Heart"},{"issue":"6","key":"1807_CR37","doi-asserted-by":"publisher","first-page":"e0217612","DOI":"10.1371\/journal.pone.0217612","volume":"14","author":"RJH Miller","year":"2019","unstructured":"Miller RJH, Heidary S, Pavlovic A, Schlachter A, Dash R, Fleischmann D, et al. Defining genotype-phenotype relationships in patients with hypertrophic cardiomyopathy using cardiovascular magnetic resonance imaging. PLoS ONE. 2019;14(6):e0217612.","journal-title":"PLoS ONE"},{"issue":"1","key":"1807_CR38","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1161\/CIRCULATIONAHA.110.985812","volume":"124","author":"MS Maron","year":"2011","unstructured":"Maron MS, Olivotto I, Harrigan C, Appelbaum E, Gibson CM, Lesser JR, et al. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Circulation. 2011;124(1):40\u20137.","journal-title":"Circulation"},{"issue":"10","key":"1807_CR39","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1093\/ehjci\/jey095","volume":"19","author":"JD Groarke","year":"2018","unstructured":"Groarke JD, Galazka PZ, Cirino AL, Lakdawala NK, Thune JJ, Bundgaard H, et al. Intrinsic mitral valve alterations in hypertrophic cardiomyopathy sarcomere mutation carriers. Eur Heart J Cardiovasc Imaging. 2018;19(10):1109\u201316.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"1_suppl","key":"1807_CR40","first-page":"S43","volume":"19","author":"L Velicki","year":"2020","unstructured":"Velicki L, Preveden A, Tafelmeier M, Olivotto I, Barlocco F, Popovic D, et al. Genetic determinants of clinical phenotype in hypertrophic cardiomyopathy. Eur J Cardiovasc Nurs. 2020;19(1_suppl):S43\u20134.","journal-title":"Eur J Cardiovasc Nurs"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-020-01807-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12872-020-01807-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-020-01807-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T13:38:51Z","timestamp":1670074731000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-020-01807-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1807"],"URL":"https:\/\/doi.org\/10.1186\/s12872-020-01807-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-36810\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-36810\/v4","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-36810\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-36810\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-36810\/v5","asserted-by":"object"}]},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"17 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the UK National Health Service Health Research Authority North East\u2014Tyne & Wear South Research Ethics Committee with reference number 18\/NE\/0318 and adopted by the Institutional Review Board of each participating institution with study participants providing written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"516"}}